Primary Navigation
Want to create or adapt books like this? Learn more about how Pressbooks supports open publishing practices.
Book Contents Navigation
1. 1.1 Overview of COPD and Asthma
2. 1.2 Current Treatment Options
3. 1.3 Overview of Triple Therapy
4. 1.4 Determining the Effectiveness of Triple versus Dual Therapy in ACO
5. 1.5 Future Direction of Triple Therapy
6. 1.6 Test Your Knowledge
7. 1.7 References
8. 2.1 Introduction
9. 2.2 Overview of Acute Respiratory Distress Syndrome (ARDS)
10. 2.3 The Limitations of Existing Therapies and Recent Advances in ARDS Research
11. 2.4 Future directions: Neutrophil Involvement in ARDS
12. 2.5 Test Your Knowledge
13. 2.6 References
14. 4.1. Overview of Alzheimer’s Disease
15. 4.2. The Gut Microbiota
16. 4.3. Quantifying the Gut Microbiome
17. 4.4. Overview of the Gut-Brain Axis
18. 4.5. Limitations and Future Directions of Alzheimer's Disease
19. 4.6. Family and Genera Abundance in Alzheimer's Disease
20. 4.7. Test Your Knowledge!
21. 4.8. References
22. 3.1 Introduction
23. 3.2 Materials: Anticancer Agents & Cell Lines
24. 3.3 Honeybee Venom and Melittin Reduce Breast Cancer Viability
25. 3.4 Honeybee Venom and Melittin Induce Breast Cancer Cell Death
26. 3.5 Bioengineering at the C-Terminus of Melittin
27. 3.6 Bioengineering at the N-Terminus of Melittin
28. 3.7 Honeybee Venom and Melittin Suppress RTK Phosphorylation
29. 3.8 Melittin Synergistically Improves Docetaxel Treatment and Reduces Immune Suppression In Vivo
30. 3.9 Critical Analysis and Limitations
31. 3.10 Study Significance
32. 3.11 Future Directions
33. 3.12 Concept Check
34. Unit 1: Introduction to Cancer & Current Strategies
35. 1.1: Introduction to Cancer
36. 1.2: Introduction to the Immune System
37. 1.3: References
38. Unit 2: Manipulation of the Immune System for an Anti-Tumor Response
39. 2.1: How Immunotherapy Fights Cancer
40. 2.2: Suppression and Activation of the T cell Response
41. 2.3: Immunotherapy: Successes & Limitations
42. 2.4: Extravasation of Leukocytes
43. 2.5: References
44. Unit 3 Learning Objectives
45. Unit 3.1: Homing of T cells in the Tumor Microenvironment
46. Unit 3.2 References
47. Unit 4: LIF and Experimental Applications of LIF
48. 4.1: Introduction to LIF
49. 4.2: RT-qPCR
50. 4.3: ChIP Sequencing
51. 4.4: Flow Cytometry
52. 4.5: ELISA
53. 4.6: References
54. Unit 5: Cancer Immunotherapy: Future Directions
55. 5.1: Current implications of checkpoint blockade therapies
56. 5.2: Immunotherapy limitations: anti-PD1 and study models
57. 5.3: Future immunotherapy extensions
58. 5.4: References
59. 6.1 Overview of Non-Small Cell Lung Cancer (NSCLC)
60. 6.2 Current and Potential Therapies for NSCLC
61. 6.3 Novel Treatment - PDL1 CAR T Cell Therapy
62. 6.4 Limitations and Future Directions for CAR T Cells
63. 6.5 Future Directions for NSCLC
64. 6.6 Test Your Knowledge!
65. 7.1 Overview of Alzheimer’s Disease
66. 7.2 Neurotropin (NTP)
67. 7.3 Quantifying the Effects of Neurotropin
68. 7.4 Markers of Alzheimer's Disease and the Effect of Neurotropin
69. 7.5 Future Directions of Neutropin
70. 7.6 Test Your Knowledge
71. 8.1 Overview of Autism Spectrum Disorder (ASD)
72. 8.2 Emerging Gut Microbiota Theories
73. 8.3 Intro to Current and Emerging Animal Models of ASD
74. 8.4 Methods for testing ASD
75. 8.5 Experiment Results
76. 8.6 Vitamin B6, the Potential Treatment for People with ASD
77. 8.7 The Challenges of ASD Research
78. 8.8 Futures directions for Vitamin B6
79. 8.9 Mental Break
80. 8.10 References
Learning Objectives Unit 3
Previous/next navigation
Selected Topics in Health and Disease (Vol. 3) Copyright © 2020 by Class of HMB422 2020 and Dr. William Ju. All Rights Reserved.
